Cargando…

Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application

INTRODUCTION: Circulating tumor cells (CTCs) play a crucial role in cancer metastasis. In this study, we introduced a novel isolation method by size of epithelial tumor cells (ISET) device with automatic isolation and staining procedure, named one-stop ISET ((os)ISET) and validated its feasibility t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Fangfang, Wang, Shuyi, Fang, Yuan, Zheng, Liang, Zhi, Xuan, Cheng, Boran, Chen, Yuanyuan, Zhang, Chunxiao, Shi, Dongdong, Song, Haibin, Cai, Congli, Zhou, Pengfei, Xiong, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356861/
https://www.ncbi.nlm.nih.gov/pubmed/27935872
http://dx.doi.org/10.18632/oncotarget.13823
_version_ 1782515933715103744
author Chen, Fangfang
Wang, Shuyi
Fang, Yuan
Zheng, Liang
Zhi, Xuan
Cheng, Boran
Chen, Yuanyuan
Zhang, Chunxiao
Shi, Dongdong
Song, Haibin
Cai, Congli
Zhou, Pengfei
Xiong, Bin
author_facet Chen, Fangfang
Wang, Shuyi
Fang, Yuan
Zheng, Liang
Zhi, Xuan
Cheng, Boran
Chen, Yuanyuan
Zhang, Chunxiao
Shi, Dongdong
Song, Haibin
Cai, Congli
Zhou, Pengfei
Xiong, Bin
author_sort Chen, Fangfang
collection PubMed
description INTRODUCTION: Circulating tumor cells (CTCs) play a crucial role in cancer metastasis. In this study, we introduced a novel isolation method by size of epithelial tumor cells (ISET) device with automatic isolation and staining procedure, named one-stop ISET ((os)ISET) and validated its feasibility to capture CTCs from cancer patients. Moreover, we aim to investigate the correlation between clinicopathologic features and CTCs in colorectal cancer (CRC) in order to explore its clinical application. RESULTS: The capture efficiency ranged from 80.3% to 88% with tumor cells spiked into medium while 67% to 78.3% with tumor cells spiked into healthy donors’ blood. In detection blood samples of 72 CRC patients, CTCs and clusters of circulating tumor cells (CTC-clusters) were detected with a positive rate of 52.8% (38/72) and 18.1% (13/72) respectively. Moreover, CTC positive rate was associated with factors of lymphatic or venous invasion, tumor depth, lymph node metastasis and TNM stage in CRC patients (p < 0.01). Lymphocyte count and neutrophil to lymphocyte ratio (NLR) were significantly different between CTC positive and negative groups (p < 0.01). MATERIALS AND METHODS: The capture efficiency of the device was tested by spiking cancer cells (MCF-7, A549, SW480, Hela) into medium or blood samples of healthy donors. Blood samples of 72 CRC patients were detected by (os)ISET device. The clinicopathologic characteristics of 72 CRC patients were collected and the association with CTC positive rate or CTC count were analyzed. CONCLUSIONS: Our (os)ISET device was feasible to capture and identify CTCs and CTC-clusters from cancer patients. In addition, our device holds a potential for application in cancer management.
format Online
Article
Text
id pubmed-5356861
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53568612017-04-20 Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application Chen, Fangfang Wang, Shuyi Fang, Yuan Zheng, Liang Zhi, Xuan Cheng, Boran Chen, Yuanyuan Zhang, Chunxiao Shi, Dongdong Song, Haibin Cai, Congli Zhou, Pengfei Xiong, Bin Oncotarget Research Paper INTRODUCTION: Circulating tumor cells (CTCs) play a crucial role in cancer metastasis. In this study, we introduced a novel isolation method by size of epithelial tumor cells (ISET) device with automatic isolation and staining procedure, named one-stop ISET ((os)ISET) and validated its feasibility to capture CTCs from cancer patients. Moreover, we aim to investigate the correlation between clinicopathologic features and CTCs in colorectal cancer (CRC) in order to explore its clinical application. RESULTS: The capture efficiency ranged from 80.3% to 88% with tumor cells spiked into medium while 67% to 78.3% with tumor cells spiked into healthy donors’ blood. In detection blood samples of 72 CRC patients, CTCs and clusters of circulating tumor cells (CTC-clusters) were detected with a positive rate of 52.8% (38/72) and 18.1% (13/72) respectively. Moreover, CTC positive rate was associated with factors of lymphatic or venous invasion, tumor depth, lymph node metastasis and TNM stage in CRC patients (p < 0.01). Lymphocyte count and neutrophil to lymphocyte ratio (NLR) were significantly different between CTC positive and negative groups (p < 0.01). MATERIALS AND METHODS: The capture efficiency of the device was tested by spiking cancer cells (MCF-7, A549, SW480, Hela) into medium or blood samples of healthy donors. Blood samples of 72 CRC patients were detected by (os)ISET device. The clinicopathologic characteristics of 72 CRC patients were collected and the association with CTC positive rate or CTC count were analyzed. CONCLUSIONS: Our (os)ISET device was feasible to capture and identify CTCs and CTC-clusters from cancer patients. In addition, our device holds a potential for application in cancer management. Impact Journals LLC 2016-12-08 /pmc/articles/PMC5356861/ /pubmed/27935872 http://dx.doi.org/10.18632/oncotarget.13823 Text en Copyright: © 2017 Chen et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Chen, Fangfang
Wang, Shuyi
Fang, Yuan
Zheng, Liang
Zhi, Xuan
Cheng, Boran
Chen, Yuanyuan
Zhang, Chunxiao
Shi, Dongdong
Song, Haibin
Cai, Congli
Zhou, Pengfei
Xiong, Bin
Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
title Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
title_full Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
title_fullStr Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
title_full_unstemmed Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
title_short Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application
title_sort feasibility of a novel one-stop iset device to capture ctcs and its clinical application
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356861/
https://www.ncbi.nlm.nih.gov/pubmed/27935872
http://dx.doi.org/10.18632/oncotarget.13823
work_keys_str_mv AT chenfangfang feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT wangshuyi feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT fangyuan feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT zhengliang feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT zhixuan feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT chengboran feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT chenyuanyuan feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT zhangchunxiao feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT shidongdong feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT songhaibin feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT caicongli feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT zhoupengfei feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication
AT xiongbin feasibilityofanovelonestopisetdevicetocapturectcsanditsclinicalapplication